Scarica l'app Stockscreener
125.45
4.02%
4.85
Pre-mercato:
125.77
0.32
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$120.60
Aprire:
$121.63
Volume 24 ore:
14.00M
Relative Volume:
1.41
Capitalizzazione di mercato:
$309.84B
Reddito:
$65.51B
Utile/perdita netta:
$8.93B
Rapporto P/E:
35.31
EPS:
3.5532
Flusso di cassa netto:
$14.12B
1 W Prestazione:
+10.17%
1M Prestazione:
+2.48%
6M Prestazione:
+17.85%
1 anno Prestazione:
+57.46%
Intervallo 1D:
$121.00
$125.96
Intervallo di 1 settimana:
$113.00
$125.96
Portata 52W:
$76.66
$125.96
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
125.45 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,127.69 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
244.88 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
243.14 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
155.12 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-02-13 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-10-13 | Ripresa | Citigroup | Neutral |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Merck & Co. lifts 2026 outlook, Keytruda and vaccines drive shares on Wall Street - Ad-hoc-news.de
Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh - TradingView
Enterprise value to revenue forward of Merck & Co., Inc. – HAN:6MK - TradingView
Merck & Co. updates pipeline and oncology focus, shares stay in the S&P 500 spotlight - Ad-hoc-news.de
Merck & Co Inc Stock (MRK) Moved Up by 4.04% on Jun 25: A Full Analysis - TradingKey
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga
Price to sales forward of Merck & Co., Inc. – HAN:6MK - TradingView
Merck & Co. updates late-stage cancer pipeline, shares on NYSE radar - Ad-hoc-news.de
Merck (MRK) Stock Gets New Outperform Rating from CICC - Insider Monkey
Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsight - GlobeNewswire Inc.
Is Merck & Co., Inc. (MRK) Strengthening Its Vaccine Portfolio With New Capvaxive Approval? - Insider Monkey
CICC Initiates Merck & Co. at Outperform With $138 Price Target - marketscreener.com
THRIVENT HEALTHCARE PORTFOLIO's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co. clears a short-term technical mark, shares extend their recent advance - Ad-hoc-news.de
Is Merck & Co Inc (MRK) Overvalued After 3.6% Rally? GF Value Sa - GuruFocus
Merck & Co Inc Stock (MRK) Moved Up by 3.23% on Jun 23: Key Drivers Unveiled - TradingKey
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study - Yahoo Finance Singapore
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co. outlines strategic pipeline moves, shares hold steady on NYSE - AD HOC NEWS
Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy - Benzinga
Merck’s Oncology Engine Is Still Accelerating (NYSE:MRK) - Seeking Alpha
Merck & Co. eyes oncology and vaccine strategy, shares tracked against big pharma peers - AD HOC NEWS
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Business Wire
Berenberg Adjusts Price Target on Merck & Co. to $125 From $115, Maintains Hold Rating - marketscreener.com
Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise - Insider Monkey
Merck & Co. Stockweekly review and pharma peer comparison - AD HOC NEWS
Penn Series Large Core Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
LVIP MFS Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
Is Merck's Recent Restructuring a Confident Pivot or a Defensive Maneuver - Kavout | AI
Merck & Co., Inc. Sued for Securities Law ViolationsInvestors - The National Law Review
Merck & Co. Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens - Benzinga
Merck granted U.S. label expansion for Capvaxive pneumococcal shot - Seeking Alpha
Merck's pneumococcal vaccine wins US approval for high-risk children, teens - Reuters
Merck & Co., Inc. (MRK) Insider Trading Activity 2026 $MRK - MarketBeat
Here’s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now - Insider Monkey
WRIGHT INVESTORS SERVICE INC's Merck & Co Inc(MRK) Holding History - GuruFocus
JPMorgan Growth Advantage Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
A Look at Merck & Co Inc (MRK) After 3.5% Decline -- GF Value $1 - GuruFocus
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co Inc Stock (MRK) Moved Down by 3.13% on Jun 15: What Signal Does It Send? - TradingKey
Panagora Asset Management Inc. Purchases 567,249 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Resources Management Corp CT ADV - MarketBeat
Vanguard Personalized Indexing Management LLC Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
MFS Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
Perryman Financial Advisory Inc. AD Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Mariner LLC Has $289.84 Million Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Kennedy Capital Management LLC Sells 16,448 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Evelyn Partners Investment Management LLP - MarketBeat
Merck & Co., Inc.: - marketscreener.com
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):